Compare DexCom, Inc. (DXCM) vs Moody's Corporation (MCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Moody's Corporation — how do they compare? DexCom, Inc. trades at $84.39 (market cap $31.86B), while Moody's Corporation trades at $460.86 (market cap $79.44B). The key difference: Moody's Corporation is far larger — about 2.5× DexCom, Inc.'s market cap, and Moody's Corporation pays a 0.9% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Moody's Corporation for 132 Days on average.
| DXCM | MCO | |
|---|---|---|
Market Cap | $31.86B | $79.44B |
Volume | 3,607,070 | 526,684 |
Sector | Health | Financials |
52-Week High | $92.34 | $539.61 |
52-Week Low | $54.84 | $412.23 |
Typical Hold Time | 62 Days | 132 Days |
Enterprise Value | $31.32B | $85.46B |
Dividend Yield | — | 0.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
MCO trades at $460.91, up 2.51% today, with a bearish technical signal but strong fundamentals including a 34.25% net income margin and consistent earnings beats. Revenue grew from $5.5B in 2022 to $7.7B in 2025, with a consensus analyst price target of $536.40. Recent news highlights a Zacks upgrade to Buy and a minority stake acquisition in PhilRatings to expand Asia-Pacific presence.
The outlook is positive given robust profitability and growth, but risks include high valuation multiples and technical weakness. Analysts are predominantly bullish, with 56% Buy ratings, suggesting upside potential if earnings momentum continues, though investors should monitor debt levels and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →
